Last reviewed · How we verify
Cromoglicate
At a glance
| Generic name | Cromoglicate |
|---|---|
| Sponsor | LEO Pharma |
| Target | Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20 |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | discontinued |
Approved indications
- Allergic Keratoconjunctivitis
- Allergic conjunctivitis
- Allergic rhinitis
- Asthma
- Asthma management
- Bronchospasm Prevention
- Giant papillary conjunctivitis
- Systemic mast cell disease
- Vernal Keratitis
- Vernal conjunctivitis
- Vernal keratoconjunctivitis
Common side effects
Key clinical trials
- Randomized, Placebo-controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib at 6 mg/kg/Day to Placebo in Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous M (Phase 3)
- Development and Validation of Test for Gastro-esophageal Reflux and Aspiration (Phase 1)
- Cromolyn Sodium for Treatment of COVID-19 Pneumonia (Phase 3)
- Phase 3 Study to Compare Oral Masitinib to Placebo in Treatment of Patients With Smouldering or Indolent Severe Systemic Mastocytosis, Unresponsive to Optimal Symptomatic Treatment (Phase 3)
- A Multicenter, Open-Label, Controlled, Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (Phase 3)
- Phase II Study of the Effect of Oral Cromolyn Sodium on Uremic Pruritus and Serum Tryptase Levels of Hemodialysed Patients (Phase 2)
- The Impact of Airway Allergic Diseases on the Health-related Quality of Life of Children and Their Parents (Caregivers): A Prospective Controlled Study (N/A)
- A Randomized, Open-label, Crossover Study to Assess the Safety, Tolerability, and Pharmacodynamics of PUL-042 Inhalation Solution in Healthy Subjects and the Effect of Pretreatment With Cromolyn Sodiu (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cromoglicate CI brief — competitive landscape report
- Cromoglicate updates RSS · CI watch RSS
- LEO Pharma portfolio CI